Key Insights
The Androgen Deprivation Therapy (ADT) market, projected to reach $8.31 billion in 2025, is anticipated to grow at a Compound Annual Growth Rate (CAGR) of 6% through 2033. This expansion is primarily driven by the increasing global incidence of prostate cancer, a key indication for ADT. Innovations in drug development yielding more effective and tolerable treatments are also accelerating adoption. Enhanced patient and physician awareness of ADT benefits, alongside improved diagnostic tools, further fuel market growth. The market is segmented by treatment modality (surgery, antiandrogen drug classes), administration route (injectable, oral), and geography. North America and Europe currently dominate due to robust healthcare infrastructure and high prostate cancer prevalence. However, Asia-Pacific is poised for significant growth, spurred by rising healthcare investments and awareness.
Androgen Deprivation Therapy Industry Market Size (In Billion)
Key market challenges include potential long-term side effects of ADT, such as osteoporosis, cardiovascular issues, and cognitive impairment, alongside the high cost of treatment, particularly in lower-income regions. The competitive landscape features major pharmaceutical players including AstraZeneca, Johnson & Johnson, and Bayer AG, engaged in continuous innovation and market share expansion. The future of the ADT market is bright, with ongoing research focused on developing novel therapies with minimized side effects and maximized efficacy. Emphasis on personalized medicine to optimize ADT regimens for individual patients is expected to drive further growth. The market anticipates increased consolidation and strategic collaborations to strengthen market positions and diversify product portfolios.
Androgen Deprivation Therapy Industry Company Market Share
Androgen Deprivation Therapy (ADT) Industry Market Report: 2019-2033
This comprehensive report provides a detailed analysis of the Androgen Deprivation Therapy (ADT) industry, covering market size, segmentation, competitive landscape, and future growth prospects. The study period spans from 2019 to 2033, with 2025 as the base and estimated year. The report offers actionable insights for industry stakeholders, including pharmaceutical companies, investors, and healthcare professionals.
Androgen Deprivation Therapy Industry Market Concentration & Innovation
The ADT market exhibits a moderately concentrated structure, with a few major players holding significant market share. However, the presence of numerous smaller companies and emerging players indicates a dynamic competitive landscape. Innovation is driven by the need for more effective and less toxic therapies, particularly in addressing the challenges of castration-resistant prostate cancer (CRPC). Regulatory frameworks, including those set by the FDA and EMA, significantly impact market access and product approval. The rise of biosimilars and the development of novel drug delivery systems contribute to a changing market dynamic. Mergers and acquisitions (M&A) activity is relatively frequent, driven by the desire for portfolio expansion and increased market share. Recent M&A deal values have ranged from xx Million to xx Million, with larger deals involving companies like AstraZeneca and AbbVie.
- Market Share: Top 5 players account for approximately 60% of the market.
- M&A Activity: Annual deal volume is estimated at xx deals, with an average deal value of xx Million.
- Innovation Drivers: Development of novel drug classes, improved drug delivery mechanisms, and personalized medicine approaches.
- Regulatory Landscape: Stringent approval processes are a major hurdle for new entrants.
- Substitutes: Limited effective substitutes currently exist for ADT in its primary applications.
Androgen Deprivation Therapy Industry Industry Trends & Insights
The ADT market is experiencing significant growth, driven by increasing prevalence of prostate cancer and other androgen-dependent diseases. The Compound Annual Growth Rate (CAGR) from 2025 to 2033 is projected to be xx%, with the market expected to reach xx Million by 2033. Technological disruptions, including advancements in targeted therapy and personalized medicine, are shaping the market. Consumer preferences are shifting towards less invasive treatments with improved tolerability. Competitive dynamics are characterized by both intense competition among established players and the emergence of innovative therapies. Market penetration is driven by increased awareness of ADT among healthcare providers and patients, coupled with expansion of healthcare infrastructure in emerging markets.
Dominant Markets & Segments in Androgen Deprivation Therapy Industry
The North American region currently holds the dominant position in the ADT market, followed by Europe. This dominance stems from several factors, including higher prevalence of prostate cancer, advanced healthcare infrastructure, and higher per capita healthcare expenditure.
- By Treatment: Prostate cancer dominates, followed by other androgen-dependent conditions.
- By Drug Class: Antiandrogens represent the largest segment due to their established efficacy and market presence.
- By Surgery: Surgical castration is significant, while other surgical interventions are less prevalent.
- By Route of Administration: Oral administration is becoming increasingly popular due to its convenience. Injectable therapies, however, still hold a substantial market share.
Key Drivers for Dominance in North America:
- High prevalence of prostate cancer
- Advanced healthcare infrastructure and access
- High healthcare spending
- Early adoption of novel therapies.
Key Drivers for Dominance in Europe:
- Significant prevalence of prostate cancer
- Well-established healthcare systems
- Governmental support for healthcare innovation
Androgen Deprivation Therapy Industry Product Developments
Recent innovations include the development of next-generation antiandrogens with improved efficacy and tolerability profiles, along with novel drug delivery systems to optimize treatment outcomes. The focus is on addressing resistance to conventional ADT therapies and improving patient quality of life. These innovations are significantly impacting market competition, driving market growth and expanding treatment options for patients.
Report Scope & Segmentation Analysis
This report segments the ADT market across multiple dimensions:
- By Treatment: Prostate cancer, breast cancer, other androgen-dependent conditions. Each segment is analyzed based on its projected growth rate, market size, and competitive landscape. Prostate cancer holds the largest share with an anticipated growth of xx%.
- By Drug Class: Antiandrogens (e.g., GnRH agonists/antagonists), other hormonal therapies. Market sizes and projections are provided for each drug class. Antiandrogens comprise the largest segment currently.
- By Surgery: Orchiectomy, other surgical interventions. We provide insights into the market shares and growth projections for each surgical approach.
- By Route of Administration: Oral, injectable. Growth rates and market sizes are provided for each administration route. Oral administration is growing rapidly while injectable remains significant.
Key Drivers of Androgen Deprivation Therapy Industry Growth
The ADT market's growth is driven by several key factors:
- Rising prevalence of prostate and other androgen-dependent cancers.
- Technological advancements leading to improved therapies.
- Increasing awareness and improved diagnostics.
- Growing geriatric population – a significant risk factor for many androgen-dependent diseases.
- Favorable regulatory landscape.
Challenges in the Androgen Deprivation Therapy Industry Sector
Several factors hinder the ADT industry's growth:
- High cost of therapies, impacting affordability and accessibility.
- Development of drug resistance in patients.
- Side effects associated with ADT, leading to treatment discontinuation.
- Intense competition among existing players.
- Stringent regulatory approvals.
Emerging Opportunities in Androgen Deprivation Therapy Industry
Significant opportunities exist in:
- Development of novel therapies to overcome drug resistance.
- Personalized medicine approaches for targeted treatment.
- Expansion into emerging markets with high unmet needs.
- Development of combination therapies with other anti-cancer agents.
- Focus on improving patient compliance and tolerability.
Leading Players in the Androgen Deprivation Therapy Industry Market
- Ferring B V
- AstraZeneca
- Bayer AG
- Astellas Pharma Inc
- Johnson and Johnson
- Foresee Pharmaceuticals Co Ltd
- Myovant Sciences GmbH
- Viatris
- Verity Pharmaceuticals Inc
- AbbVie Inc
- Bristol-Myers Squibb Company
- Tolmar Pharmaceuticals Inc
Key Developments in Androgen Deprivation Therapy Industry Industry
- March 2023: The European Commission approved Nubeqa (darolutamide), an oral androgen receptor inhibitor (ARi), plus androgen deprivation therapy (ADT) in combination with docetaxel, for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC). This approval significantly expands treatment options for mHSPC.
- March 2023: OliX Pharmaceuticals, Inc. announced the approval of a Phase 1 clinical trial for OLX72021, a potential treatment for androgenic alopecia. This development signifies a potential expansion of ADT applications beyond cancer treatment.
Strategic Outlook for Androgen Deprivation Therapy Industry Market
The ADT market is poised for continued growth, driven by the increasing prevalence of androgen-dependent diseases and the ongoing development of innovative therapies. Future market potential is significant, particularly with advances in personalized medicine and combination therapies. Companies with a strong focus on innovation, robust clinical pipelines, and effective market access strategies are expected to dominate the market. Addressing the challenges of drug resistance and improving patient outcomes remain crucial for future success in the ADT market.
Androgen Deprivation Therapy Industry Segmentation
-
1. Treatment
-
1.1. By Drug Class
- 1.1.1. Luteiniz
- 1.1.2. Antiandrogens
- 1.2. By Surgery
-
1.1. By Drug Class
-
2. Route of Administration
- 2.1. Injectable
- 2.2. Oral
Androgen Deprivation Therapy Industry Segmentation By Geography
-
1. North America
- 1.1. United States
- 1.2. Canada
- 1.3. Mexico
-
2. Europe
- 2.1. Germany
- 2.2. United Kingdom
- 2.3. France
- 2.4. Italy
- 2.5. Spain
- 2.6. Rest of Europe
-
3. Asia Pacific
- 3.1. China
- 3.2. Japan
- 3.3. India
- 3.4. Australia
- 3.5. South Korea
- 3.6. Rest of Asia Pacific
-
4. Middle East and Africa
- 4.1. GCC
- 4.2. South Africa
- 4.3. Rest of Middle East and Africa
-
5. South America
- 5.1. Brazil
- 5.2. Argentina
- 5.3. Rest of South America
Androgen Deprivation Therapy Industry Regional Market Share
Geographic Coverage of Androgen Deprivation Therapy Industry
Androgen Deprivation Therapy Industry REPORT HIGHLIGHTS
| Aspects | Details |
|---|---|
| Study Period | 2020-2034 |
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026-2034 |
| Historical Period | 2020-2025 |
| Growth Rate | CAGR of 6% from 2020-2034 |
| Segmentation |
|
Table of Contents
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 2.1. Introduction
- 3. Market Dynamics
- 3.1. Introduction
- 3.2. Market Drivers
- 3.2.1. Rising Burden of Prostrate Cancer; Rising Research and Development Activities
- 3.3. Market Restrains
- 3.3.1. Poor Reimbursement and Increasing Side Effects
- 3.4. Market Trends
- 3.4.1. Antiandrogen Sub Segment Within Drug Class Segment is Expected to Witness a Strong Growth Over the Forecast Period
- 4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
- 5. Global Androgen Deprivation Therapy Industry Analysis, Insights and Forecast, 2020-2032
- 5.1. Market Analysis, Insights and Forecast - by Treatment
- 5.1.1. By Drug Class
- 5.1.1.1. Luteiniz
- 5.1.1.2. Antiandrogens
- 5.1.2. By Surgery
- 5.1.1. By Drug Class
- 5.2. Market Analysis, Insights and Forecast - by Route of Administration
- 5.2.1. Injectable
- 5.2.2. Oral
- 5.3. Market Analysis, Insights and Forecast - by Region
- 5.3.1. North America
- 5.3.2. Europe
- 5.3.3. Asia Pacific
- 5.3.4. Middle East and Africa
- 5.3.5. South America
- 5.1. Market Analysis, Insights and Forecast - by Treatment
- 6. North America Androgen Deprivation Therapy Industry Analysis, Insights and Forecast, 2020-2032
- 6.1. Market Analysis, Insights and Forecast - by Treatment
- 6.1.1. By Drug Class
- 6.1.1.1. Luteiniz
- 6.1.1.2. Antiandrogens
- 6.1.2. By Surgery
- 6.1.1. By Drug Class
- 6.2. Market Analysis, Insights and Forecast - by Route of Administration
- 6.2.1. Injectable
- 6.2.2. Oral
- 6.1. Market Analysis, Insights and Forecast - by Treatment
- 7. Europe Androgen Deprivation Therapy Industry Analysis, Insights and Forecast, 2020-2032
- 7.1. Market Analysis, Insights and Forecast - by Treatment
- 7.1.1. By Drug Class
- 7.1.1.1. Luteiniz
- 7.1.1.2. Antiandrogens
- 7.1.2. By Surgery
- 7.1.1. By Drug Class
- 7.2. Market Analysis, Insights and Forecast - by Route of Administration
- 7.2.1. Injectable
- 7.2.2. Oral
- 7.1. Market Analysis, Insights and Forecast - by Treatment
- 8. Asia Pacific Androgen Deprivation Therapy Industry Analysis, Insights and Forecast, 2020-2032
- 8.1. Market Analysis, Insights and Forecast - by Treatment
- 8.1.1. By Drug Class
- 8.1.1.1. Luteiniz
- 8.1.1.2. Antiandrogens
- 8.1.2. By Surgery
- 8.1.1. By Drug Class
- 8.2. Market Analysis, Insights and Forecast - by Route of Administration
- 8.2.1. Injectable
- 8.2.2. Oral
- 8.1. Market Analysis, Insights and Forecast - by Treatment
- 9. Middle East and Africa Androgen Deprivation Therapy Industry Analysis, Insights and Forecast, 2020-2032
- 9.1. Market Analysis, Insights and Forecast - by Treatment
- 9.1.1. By Drug Class
- 9.1.1.1. Luteiniz
- 9.1.1.2. Antiandrogens
- 9.1.2. By Surgery
- 9.1.1. By Drug Class
- 9.2. Market Analysis, Insights and Forecast - by Route of Administration
- 9.2.1. Injectable
- 9.2.2. Oral
- 9.1. Market Analysis, Insights and Forecast - by Treatment
- 10. South America Androgen Deprivation Therapy Industry Analysis, Insights and Forecast, 2020-2032
- 10.1. Market Analysis, Insights and Forecast - by Treatment
- 10.1.1. By Drug Class
- 10.1.1.1. Luteiniz
- 10.1.1.2. Antiandrogens
- 10.1.2. By Surgery
- 10.1.1. By Drug Class
- 10.2. Market Analysis, Insights and Forecast - by Route of Administration
- 10.2.1. Injectable
- 10.2.2. Oral
- 10.1. Market Analysis, Insights and Forecast - by Treatment
- 11. Competitive Analysis
- 11.1. Global Market Share Analysis 2025
- 11.2. Company Profiles
- 11.2.1 Ferring B V
- 11.2.1.1. Overview
- 11.2.1.2. Products
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Financials (Based on Availability)
- 11.2.2 Astrazeneca
- 11.2.2.1. Overview
- 11.2.2.2. Products
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Financials (Based on Availability)
- 11.2.3 Bayer AG
- 11.2.3.1. Overview
- 11.2.3.2. Products
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Financials (Based on Availability)
- 11.2.4 Astellas Pharma Inc
- 11.2.4.1. Overview
- 11.2.4.2. Products
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Financials (Based on Availability)
- 11.2.5 Johnson and Johnson
- 11.2.5.1. Overview
- 11.2.5.2. Products
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Financials (Based on Availability)
- 11.2.6 Foresee Pharmaceuticals Co Ltd
- 11.2.6.1. Overview
- 11.2.6.2. Products
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Financials (Based on Availability)
- 11.2.7 Myovant Sciences GmbH
- 11.2.7.1. Overview
- 11.2.7.2. Products
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Financials (Based on Availability)
- 11.2.8 Viatris
- 11.2.8.1. Overview
- 11.2.8.2. Products
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Financials (Based on Availability)
- 11.2.9 Verity Pharmaceuticals Inc
- 11.2.9.1. Overview
- 11.2.9.2. Products
- 11.2.9.3. SWOT Analysis
- 11.2.9.4. Recent Developments
- 11.2.9.5. Financials (Based on Availability)
- 11.2.10 AbbVie Inc
- 11.2.10.1. Overview
- 11.2.10.2. Products
- 11.2.10.3. SWOT Analysis
- 11.2.10.4. Recent Developments
- 11.2.10.5. Financials (Based on Availability)
- 11.2.11 Bristol-Myers Squibb Company*List Not Exhaustive
- 11.2.11.1. Overview
- 11.2.11.2. Products
- 11.2.11.3. SWOT Analysis
- 11.2.11.4. Recent Developments
- 11.2.11.5. Financials (Based on Availability)
- 11.2.12 Tolmar Pharmaceuticals Inc
- 11.2.12.1. Overview
- 11.2.12.2. Products
- 11.2.12.3. SWOT Analysis
- 11.2.12.4. Recent Developments
- 11.2.12.5. Financials (Based on Availability)
- 11.2.1 Ferring B V
List of Figures
- Figure 1: Global Androgen Deprivation Therapy Industry Revenue Breakdown (billion, %) by Region 2025 & 2033
- Figure 2: North America Androgen Deprivation Therapy Industry Revenue (billion), by Treatment 2025 & 2033
- Figure 3: North America Androgen Deprivation Therapy Industry Revenue Share (%), by Treatment 2025 & 2033
- Figure 4: North America Androgen Deprivation Therapy Industry Revenue (billion), by Route of Administration 2025 & 2033
- Figure 5: North America Androgen Deprivation Therapy Industry Revenue Share (%), by Route of Administration 2025 & 2033
- Figure 6: North America Androgen Deprivation Therapy Industry Revenue (billion), by Country 2025 & 2033
- Figure 7: North America Androgen Deprivation Therapy Industry Revenue Share (%), by Country 2025 & 2033
- Figure 8: Europe Androgen Deprivation Therapy Industry Revenue (billion), by Treatment 2025 & 2033
- Figure 9: Europe Androgen Deprivation Therapy Industry Revenue Share (%), by Treatment 2025 & 2033
- Figure 10: Europe Androgen Deprivation Therapy Industry Revenue (billion), by Route of Administration 2025 & 2033
- Figure 11: Europe Androgen Deprivation Therapy Industry Revenue Share (%), by Route of Administration 2025 & 2033
- Figure 12: Europe Androgen Deprivation Therapy Industry Revenue (billion), by Country 2025 & 2033
- Figure 13: Europe Androgen Deprivation Therapy Industry Revenue Share (%), by Country 2025 & 2033
- Figure 14: Asia Pacific Androgen Deprivation Therapy Industry Revenue (billion), by Treatment 2025 & 2033
- Figure 15: Asia Pacific Androgen Deprivation Therapy Industry Revenue Share (%), by Treatment 2025 & 2033
- Figure 16: Asia Pacific Androgen Deprivation Therapy Industry Revenue (billion), by Route of Administration 2025 & 2033
- Figure 17: Asia Pacific Androgen Deprivation Therapy Industry Revenue Share (%), by Route of Administration 2025 & 2033
- Figure 18: Asia Pacific Androgen Deprivation Therapy Industry Revenue (billion), by Country 2025 & 2033
- Figure 19: Asia Pacific Androgen Deprivation Therapy Industry Revenue Share (%), by Country 2025 & 2033
- Figure 20: Middle East and Africa Androgen Deprivation Therapy Industry Revenue (billion), by Treatment 2025 & 2033
- Figure 21: Middle East and Africa Androgen Deprivation Therapy Industry Revenue Share (%), by Treatment 2025 & 2033
- Figure 22: Middle East and Africa Androgen Deprivation Therapy Industry Revenue (billion), by Route of Administration 2025 & 2033
- Figure 23: Middle East and Africa Androgen Deprivation Therapy Industry Revenue Share (%), by Route of Administration 2025 & 2033
- Figure 24: Middle East and Africa Androgen Deprivation Therapy Industry Revenue (billion), by Country 2025 & 2033
- Figure 25: Middle East and Africa Androgen Deprivation Therapy Industry Revenue Share (%), by Country 2025 & 2033
- Figure 26: South America Androgen Deprivation Therapy Industry Revenue (billion), by Treatment 2025 & 2033
- Figure 27: South America Androgen Deprivation Therapy Industry Revenue Share (%), by Treatment 2025 & 2033
- Figure 28: South America Androgen Deprivation Therapy Industry Revenue (billion), by Route of Administration 2025 & 2033
- Figure 29: South America Androgen Deprivation Therapy Industry Revenue Share (%), by Route of Administration 2025 & 2033
- Figure 30: South America Androgen Deprivation Therapy Industry Revenue (billion), by Country 2025 & 2033
- Figure 31: South America Androgen Deprivation Therapy Industry Revenue Share (%), by Country 2025 & 2033
List of Tables
- Table 1: Global Androgen Deprivation Therapy Industry Revenue billion Forecast, by Treatment 2020 & 2033
- Table 2: Global Androgen Deprivation Therapy Industry Revenue billion Forecast, by Route of Administration 2020 & 2033
- Table 3: Global Androgen Deprivation Therapy Industry Revenue billion Forecast, by Region 2020 & 2033
- Table 4: Global Androgen Deprivation Therapy Industry Revenue billion Forecast, by Treatment 2020 & 2033
- Table 5: Global Androgen Deprivation Therapy Industry Revenue billion Forecast, by Route of Administration 2020 & 2033
- Table 6: Global Androgen Deprivation Therapy Industry Revenue billion Forecast, by Country 2020 & 2033
- Table 7: United States Androgen Deprivation Therapy Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 8: Canada Androgen Deprivation Therapy Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 9: Mexico Androgen Deprivation Therapy Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 10: Global Androgen Deprivation Therapy Industry Revenue billion Forecast, by Treatment 2020 & 2033
- Table 11: Global Androgen Deprivation Therapy Industry Revenue billion Forecast, by Route of Administration 2020 & 2033
- Table 12: Global Androgen Deprivation Therapy Industry Revenue billion Forecast, by Country 2020 & 2033
- Table 13: Germany Androgen Deprivation Therapy Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 14: United Kingdom Androgen Deprivation Therapy Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 15: France Androgen Deprivation Therapy Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 16: Italy Androgen Deprivation Therapy Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 17: Spain Androgen Deprivation Therapy Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 18: Rest of Europe Androgen Deprivation Therapy Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 19: Global Androgen Deprivation Therapy Industry Revenue billion Forecast, by Treatment 2020 & 2033
- Table 20: Global Androgen Deprivation Therapy Industry Revenue billion Forecast, by Route of Administration 2020 & 2033
- Table 21: Global Androgen Deprivation Therapy Industry Revenue billion Forecast, by Country 2020 & 2033
- Table 22: China Androgen Deprivation Therapy Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 23: Japan Androgen Deprivation Therapy Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 24: India Androgen Deprivation Therapy Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 25: Australia Androgen Deprivation Therapy Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 26: South Korea Androgen Deprivation Therapy Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 27: Rest of Asia Pacific Androgen Deprivation Therapy Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 28: Global Androgen Deprivation Therapy Industry Revenue billion Forecast, by Treatment 2020 & 2033
- Table 29: Global Androgen Deprivation Therapy Industry Revenue billion Forecast, by Route of Administration 2020 & 2033
- Table 30: Global Androgen Deprivation Therapy Industry Revenue billion Forecast, by Country 2020 & 2033
- Table 31: GCC Androgen Deprivation Therapy Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 32: South Africa Androgen Deprivation Therapy Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 33: Rest of Middle East and Africa Androgen Deprivation Therapy Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 34: Global Androgen Deprivation Therapy Industry Revenue billion Forecast, by Treatment 2020 & 2033
- Table 35: Global Androgen Deprivation Therapy Industry Revenue billion Forecast, by Route of Administration 2020 & 2033
- Table 36: Global Androgen Deprivation Therapy Industry Revenue billion Forecast, by Country 2020 & 2033
- Table 37: Brazil Androgen Deprivation Therapy Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 38: Argentina Androgen Deprivation Therapy Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 39: Rest of South America Androgen Deprivation Therapy Industry Revenue (billion) Forecast, by Application 2020 & 2033
Frequently Asked Questions
1. What is the projected Compound Annual Growth Rate (CAGR) of the Androgen Deprivation Therapy Industry?
The projected CAGR is approximately 6%.
2. Which companies are prominent players in the Androgen Deprivation Therapy Industry?
Key companies in the market include Ferring B V, Astrazeneca, Bayer AG, Astellas Pharma Inc, Johnson and Johnson, Foresee Pharmaceuticals Co Ltd, Myovant Sciences GmbH, Viatris, Verity Pharmaceuticals Inc, AbbVie Inc, Bristol-Myers Squibb Company*List Not Exhaustive, Tolmar Pharmaceuticals Inc.
3. What are the main segments of the Androgen Deprivation Therapy Industry?
The market segments include Treatment, Route of Administration.
4. Can you provide details about the market size?
The market size is estimated to be USD 8.31 billion as of 2022.
5. What are some drivers contributing to market growth?
Rising Burden of Prostrate Cancer; Rising Research and Development Activities.
6. What are the notable trends driving market growth?
Antiandrogen Sub Segment Within Drug Class Segment is Expected to Witness a Strong Growth Over the Forecast Period.
7. Are there any restraints impacting market growth?
Poor Reimbursement and Increasing Side Effects.
8. Can you provide examples of recent developments in the market?
March 2023: The European Commission approved Nubeqa (darolutamide), an oral androgen receptor inhibitor (ARi), plus androgen deprivation therapy (ADT) in combination with docetaxel, for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC).
9. What pricing options are available for accessing the report?
Pricing options include single-user, multi-user, and enterprise licenses priced at USD 4750, USD 5250, and USD 8750 respectively.
10. Is the market size provided in terms of value or volume?
The market size is provided in terms of value, measured in billion.
11. Are there any specific market keywords associated with the report?
Yes, the market keyword associated with the report is "Androgen Deprivation Therapy Industry," which aids in identifying and referencing the specific market segment covered.
12. How do I determine which pricing option suits my needs best?
The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.
13. Are there any additional resources or data provided in the Androgen Deprivation Therapy Industry report?
While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.
14. How can I stay updated on further developments or reports in the Androgen Deprivation Therapy Industry?
To stay informed about further developments, trends, and reports in the Androgen Deprivation Therapy Industry, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.
Methodology
Step 1 - Identification of Relevant Samples Size from Population Database
Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)
Note*: In applicable scenarios
Step 3 - Data Sources
Primary Research
- Web Analytics
- Survey Reports
- Research Institute
- Latest Research Reports
- Opinion Leaders
Secondary Research
- Annual Reports
- White Paper
- Latest Press Release
- Industry Association
- Paid Database
- Investor Presentations
Step 4 - Data Triangulation
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence
